Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2003

Open Access 01-12-2003 | Research

Vision related quality of life and topical glaucoma treatment side effects

Authors: Jean-Philippe Nordmann, Nadia Auzanneau, Séverine Ricard, Gilles Berdeaux

Published in: Health and Quality of Life Outcomes | Issue 1/2003

Login to get access

Abstract

Background

Local tolerance of topical glaucoma treatment is important to achieve a good compliance. The aim of this study was to evaluate the consequences of local anti-glaucoma drug side effects on the vision-related quality of life (QoL).

Methods

A mail survey was sent to 20,000 homes of a panel representative of the French population asking whether one member of the family was suffering from ocular hypertension (OHT) or glaucoma. (POAG) A computer-assisted telephone interviewing system was used to confirm self-reported glaucoma, to describe the disease and its treatment, and medical item consumption. Vision-related QoL was assessed with the NEI-VFQ-25 (National Eye Institute Visual – Function Questionnaire) and local tolerance with the COMTOL (Comparison of Ophthalmic Medications for TOLerability).

Results

13,352 homes (66.7%) answered the mail. 581 people declared they were suffering from glaucoma or OHT. Prevalence was 1.8%, increasing with age. 204 patients were selected at random Their NEI-VFQ-25 global score showed an overall good QoL. Two domain scores showed some deterioration: general health and driving. 62.4% of the patients cited at least one local side effect. 25.4% had burning, 20.8% blurred vision and 20.2% tearing. Poor vision related QoL was associated with the presence of local side effects leading to poor perceived treatment satisfaction. Dissatisfied patients visited their ophthalmologist more frequently.

Conclusion

Based on a representative French sample, poor vision related QoL was associated with topical drug side effects that also impact patient satisfaction and compliance. Longitudinal data collection should be performed to confirm our findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Goldstein H: Magnitude and causes of blindness : Sources and limitations of data. In clinical ophthalmology (Edited by: Freemann JS). Lippincott Company, Philadelphia, The USA 1990,5(52):1–10. Goldstein H: Magnitude and causes of blindness : Sources and limitations of data. In clinical ophthalmology (Edited by: Freemann JS). Lippincott Company, Philadelphia, The USA 1990,5(52):1–10.
2.
go back to reference Mitchell P, Smith W, Attebo K, Healey PR: Prevalence of open-angle glaucoma in Australia. The Blue Mountains eye study. Ophthalmology 1996, 103: 1661–9.PubMedCrossRef Mitchell P, Smith W, Attebo K, Healey PR: Prevalence of open-angle glaucoma in Australia. The Blue Mountains eye study. Ophthalmology 1996, 103: 1661–9.PubMedCrossRef
3.
go back to reference Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ: Prevalence of glaucoma. The Beaver Dam Eye study,. Ophthalmology 1992, 99: 1499–1504.PubMedCrossRef Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ: Prevalence of glaucoma. The Beaver Dam Eye study,. Ophthalmology 1992, 99: 1499–1504.PubMedCrossRef
4.
go back to reference Ekstrom C: Prevalence of open-angle glaucoma in central Sweden. The Tierp glaucoma survey. Acta Ophthalmologica Scandinavica 1996, 74: 107–12.PubMedCrossRef Ekstrom C: Prevalence of open-angle glaucoma in central Sweden. The Tierp glaucoma survey. Acta Ophthalmologica Scandinavica 1996, 74: 107–12.PubMedCrossRef
5.
go back to reference Bengtsonn B: The prevalence of glaucoma. British Journal ofOphthalmology 1981, 65: 46–9.CrossRef Bengtsonn B: The prevalence of glaucoma. British Journal ofOphthalmology 1981, 65: 46–9.CrossRef
6.
go back to reference Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR: The Framingham eye study. I. Outline and major prevalence findings. II. Associations of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. American Journal of Epidemiology 1977, 106: 33–41.PubMed Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR: The Framingham eye study. I. Outline and major prevalence findings. II. Associations of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. American Journal of Epidemiology 1977, 106: 33–41.PubMed
7.
go back to reference Kahn HA, Milton RC: Alternative definitions of open angle glaucoma. Effects on prevalence and associations in the Framingham Eye Study. Archives of Ophthalmology 1980, 98: 2172–7.PubMedCrossRef Kahn HA, Milton RC: Alternative definitions of open angle glaucoma. Effects on prevalence and associations in the Framingham Eye Study. Archives of Ophthalmology 1980, 98: 2172–7.PubMedCrossRef
8.
go back to reference Kahn HA, Milton RC: Revised Framingham eye study prevalence of glaucoma and diabetic retinopathy. American Journal of Epidemiology 1980, 111: 769–76.PubMed Kahn HA, Milton RC: Revised Framingham eye study prevalence of glaucoma and diabetic retinopathy. American Journal of Epidemiology 1980, 111: 769–76.PubMed
9.
go back to reference Martinez GS, Campbell AJ, Reinken J, Allan BC: Prevalence of ocular disease in population 65 years old and older. American Journal of Ophthalmology 1982, 94: 181–189.PubMedCrossRef Martinez GS, Campbell AJ, Reinken J, Allan BC: Prevalence of ocular disease in population 65 years old and older. American Journal of Ophthalmology 1982, 94: 181–189.PubMedCrossRef
10.
go back to reference Podgor MJ, Leske MC, Ederer F: Incidence estimates for lens changes, macular changes, open-angle glaucoma and diabetic retinopathy. American Journal of Epidemiology 1983, 118: 206–212.PubMed Podgor MJ, Leske MC, Ederer F: Incidence estimates for lens changes, macular changes, open-angle glaucoma and diabetic retinopathy. American Journal of Epidemiology 1983, 118: 206–212.PubMed
11.
go back to reference Tuck MW, Crick RP: The age distribution of primary open angle glaucoma. Ophthalmic Epidemiology 1998, 5: 173–183. 10.1076/opep.5.4.173.4192PubMedCrossRef Tuck MW, Crick RP: The age distribution of primary open angle glaucoma. Ophthalmic Epidemiology 1998, 5: 173–183. 10.1076/opep.5.4.173.4192PubMedCrossRef
12.
go back to reference Quigley HA, Vitale S: Models of open-angle glaucoma prevalence and incidence in the United States. Investigative Ophthalmology and Visual Science 1997, 38: 83–91.PubMed Quigley HA, Vitale S: Models of open-angle glaucoma prevalence and incidence in the United States. Investigative Ophthalmology and Visual Science 1997, 38: 83–91.PubMed
13.
go back to reference Armaly MF: Ocular pressure and visual fields : A ten-year follow-up study. Arch Ophthalmol 1969, 81: 25–44.PubMedCrossRef Armaly MF: Ocular pressure and visual fields : A ten-year follow-up study. Arch Ophthalmol 1969, 81: 25–44.PubMedCrossRef
14.
go back to reference Rota-Bartelink AM, Pitt A, Story I: Influence of diurnal variation on the intraocular pressure measurement of treated primary open-angle glaucoma during office hours. J Glaucoma 1996,5(6):410–5.PubMedCrossRef Rota-Bartelink AM, Pitt A, Story I: Influence of diurnal variation on the intraocular pressure measurement of treated primary open-angle glaucoma during office hours. J Glaucoma 1996,5(6):410–5.PubMedCrossRef
15.
go back to reference Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000,9(2):134–42.PubMedCrossRef Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000,9(2):134–42.PubMedCrossRef
16.
go back to reference Gonzalez I, Pablo LE, Pueyo M, Ferrer E, Melcon B, Abecia E, Honrubia FM: Assessment of diurnal tensional curve in early glaucoma damage. Int Ophthalmol 1997,20(1–3):113–5. Gonzalez I, Pablo LE, Pueyo M, Ferrer E, Melcon B, Abecia E, Honrubia FM: Assessment of diurnal tensional curve in early glaucoma damage. Int Ophthalmol 1997,20(1–3):113–5.
17.
go back to reference Zeimer RC, Wilensky JT, Gieser DK, Viana MAG: Association between intra-ocular pressure peaks and progression of visual field loss. Ophthalmology 1991,98(1):64–69.PubMedCrossRef Zeimer RC, Wilensky JT, Gieser DK, Viana MAG: Association between intra-ocular pressure peaks and progression of visual field loss. Ophthalmology 1991,98(1):64–69.PubMedCrossRef
18.
go back to reference The AGIS investigators: The advanced glaucoma intervention study (AGIS) : 7. The relationship between control of intra-ocular pressure and visual field deterioration. American Journal of Ophthalmology 2000,130(4):429–440. 10.1016/S0002-9394(00)00538-9CrossRef The AGIS investigators: The advanced glaucoma intervention study (AGIS) : 7. The relationship between control of intra-ocular pressure and visual field deterioration. American Journal of Ophthalmology 2000,130(4):429–440. 10.1016/S0002-9394(00)00538-9CrossRef
19.
go back to reference Kitazawa Y, Horie T, Aoki S: Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 1977, 95: 1180–1189.PubMedCrossRef Kitazawa Y, Horie T, Aoki S: Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 1977, 95: 1180–1189.PubMedCrossRef
20.
go back to reference Anderson DR: The management of elevated intraocular pressure with normal optic discs and visual fields. Surv Ophthalmol 1977, 21: 479–89.PubMedCrossRef Anderson DR: The management of elevated intraocular pressure with normal optic discs and visual fields. Surv Ophthalmol 1977, 21: 479–89.PubMedCrossRef
21.
go back to reference Fingeret M: Glaucoma medications, glaucoma therapy, and the evolving paradigm. J Am Optom Assoc 1998,69(2):115–21.PubMed Fingeret M: Glaucoma medications, glaucoma therapy, and the evolving paradigm. J Am Optom Assoc 1998,69(2):115–21.PubMed
22.
go back to reference Reyes E, Izquierdo NJ, Blasini M: Adverse drugs reactions associated with glaucoma medications. Bol Asoc Med P R 1997,89(4–6):51–5.PubMed Reyes E, Izquierdo NJ, Blasini M: Adverse drugs reactions associated with glaucoma medications. Bol Asoc Med P R 1997,89(4–6):51–5.PubMed
23.
go back to reference Odberg T, Jakobsen JE, Hultgren SJ, Halseide R: The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmologica Scandinavica 2001, 79: 121–4. 10.1034/j.1600-0420.2001.079002121.xPubMedCrossRef Odberg T, Jakobsen JE, Hultgren SJ, Halseide R: The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmologica Scandinavica 2001, 79: 121–4. 10.1034/j.1600-0420.2001.079002121.xPubMedCrossRef
24.
go back to reference Odberg T, Jakobsen JE, Hultgren SJ, Halseide R: The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmologica Scandinavica 2001, 79: 116–20. 10.1034/j.1600-0420.2001.079002116.xPubMedCrossRef Odberg T, Jakobsen JE, Hultgren SJ, Halseide R: The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmologica Scandinavica 2001, 79: 116–20. 10.1034/j.1600-0420.2001.079002116.xPubMedCrossRef
25.
go back to reference Mills RP, Janz NK, Wren PA, Guire KE: Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). Journal of Glaucoma 2001, 10: 192–198. 10.1097/00061198-200106000-00008PubMedCrossRef Mills RP, Janz NK, Wren PA, Guire KE: Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). Journal of Glaucoma 2001, 10: 192–198. 10.1097/00061198-200106000-00008PubMedCrossRef
26.
go back to reference Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE: Quality of life in newly diagnosed glaucoma patients : The collaborative Initial Glaucoma Treatment Study. Ophthalmology 2001, 108: 887–97. 10.1016/S0161-6420(00)00624-2PubMedCrossRef Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE: Quality of life in newly diagnosed glaucoma patients : The collaborative Initial Glaucoma Treatment Study. Ophthalmology 2001, 108: 887–97. 10.1016/S0161-6420(00)00624-2PubMedCrossRef
27.
go back to reference Sherwood MB, Garcia-Siekavizza A, Meltzer MI, Hebert A, Burns AF, McGorray S: Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology 1998, 105: 561–6. 10.1016/S0161-6420(98)93043-3PubMedCrossRef Sherwood MB, Garcia-Siekavizza A, Meltzer MI, Hebert A, Burns AF, McGorray S: Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology 1998, 105: 561–6. 10.1016/S0161-6420(98)93043-3PubMedCrossRef
28.
go back to reference Mills RP: Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Transactions of the American Ophthalmological Society 1998, 96: 753–812.PubMedCentralPubMed Mills RP: Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Transactions of the American Ophthalmological Society 1998, 96: 753–812.PubMedCentralPubMed
29.
go back to reference Parrish RK, Gedde SJ, Scott IU, Feuer WJ, Schiffman JC, Mangione CM, Montenegro-Piniella A: Visual function and quality of life among patients with glaucoma. Archives of Ophthalmology 1997, 115: 1447–55.PubMedCrossRef Parrish RK, Gedde SJ, Scott IU, Feuer WJ, Schiffman JC, Mangione CM, Montenegro-Piniella A: Visual function and quality of life among patients with glaucoma. Archives of Ophthalmology 1997, 115: 1447–55.PubMedCrossRef
30.
go back to reference Parrish RK: Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma. Transactions of the American Ophthalmological Society 1996, 94: 919–1028.PubMedCentralPubMed Parrish RK: Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma. Transactions of the American Ophthalmological Society 1996, 94: 919–1028.PubMedCentralPubMed
31.
go back to reference Wilson MR, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, Win J, Lai A: Functional status and well being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology 1998, 105: 2112–6. 10.1016/S0161-6420(98)91135-6PubMedCrossRef Wilson MR, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, Win J, Lai A: Functional status and well being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology 1998, 105: 2112–6. 10.1016/S0161-6420(98)91135-6PubMedCrossRef
32.
go back to reference Marchetti A, Magar R, An P, Nichol M: Clinical and economic impact of new trends in glaucoma treatment. MedGenMed [serial online] 2001, 3: 6. Marchetti A, Magar R, An P, Nichol M: Clinical and economic impact of new trends in glaucoma treatment. MedGenMed [serial online] 2001, 3: 6.
33.
go back to reference Cantor LB, Hoop J, Katz LJ, Flartey K, Alphagan/Betaxol Clinical Study Group: Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure. Clin Ther 2001, 23: 1032–9. 10.1016/S0149-2918(01)80089-8PubMedCrossRef Cantor LB, Hoop J, Katz LJ, Flartey K, Alphagan/Betaxol Clinical Study Group: Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure. Clin Ther 2001, 23: 1032–9. 10.1016/S0149-2918(01)80089-8PubMedCrossRef
34.
go back to reference Javitt JC, Schiffman RM: Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. Journal of Glaucoma 2000, 9: 224–34.PubMedCrossRef Javitt JC, Schiffman RM: Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. Journal of Glaucoma 2000, 9: 224–34.PubMedCrossRef
35.
go back to reference Javitt J, Goldberg I: Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. Journal of Glaucoma 2000, 9: 398–408.PubMedCrossRef Javitt J, Goldberg I: Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. Journal of Glaucoma 2000, 9: 398–408.PubMedCrossRef
36.
go back to reference Lee DA, Gornbein JA: Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. Journal of Glaucoma 2001, 10: 220–6. 10.1097/00061198-200106000-00014PubMedCrossRef Lee DA, Gornbein JA: Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. Journal of Glaucoma 2001, 10: 220–6. 10.1097/00061198-200106000-00014PubMedCrossRef
37.
go back to reference Strohmaier K, Snyder E, Adamsons I: A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: patient preference and impact on daily life. Journal of the American Optometric Association 1998, 69: 441–51.PubMed Strohmaier K, Snyder E, Adamsons I: A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: patient preference and impact on daily life. Journal of the American Optometric Association 1998, 69: 441–51.PubMed
38.
go back to reference Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R, Sherwood M, Meng K, Mangione CM: Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol 1997, 115: 777–84.PubMedCrossRef Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R, Sherwood M, Meng K, Mangione CM: Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol 1997, 115: 777–84.PubMedCrossRef
39.
go back to reference Wandell PE, Lundstrom M, Brorsson B, Aberg H: Quality of life among patients with glaucoma in Sweden. Acta Ophthalmol Scand 1997, 75: 584–8.PubMedCrossRef Wandell PE, Lundstrom M, Brorsson B, Aberg H: Quality of life among patients with glaucoma in Sweden. Acta Ophthalmol Scand 1997, 75: 584–8.PubMedCrossRef
40.
go back to reference Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA: Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology 1997, 104: 334–42.PubMedCrossRef Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA: Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology 1997, 104: 334–42.PubMedCrossRef
41.
go back to reference Barber BL, Santanello NC: Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics 1995, 33: 598–604.PubMed Barber BL, Santanello NC: Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. International Journal of Clinical Pharmacology and Therapeutics 1995, 33: 598–604.PubMed
43.
go back to reference Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: Etude pharmaco-épidémiologique de la consommation des antidépresseurs en population générale. L'Encéphale 1996, Sp I.: 39–48. Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: Etude pharmaco-épidémiologique de la consommation des antidépresseurs en population générale. L'Encéphale 1996, Sp I.: 39–48.
44.
go back to reference Frexinos J, Denis P, Allemand H, Allouche S, Los F, Bonnelye G: Etude descriptive des symptômes fonctionnels digestifs dans la population générale française. Gastroenterol Clin Biol 1998, 22: 785–91.PubMed Frexinos J, Denis P, Allemand H, Allouche S, Los F, Bonnelye G: Etude descriptive des symptômes fonctionnels digestifs dans la population générale française. Gastroenterol Clin Biol 1998, 22: 785–91.PubMed
45.
go back to reference Antona D, Guérin N: Couverture vaccinale rougeole – rubéole – oreillons en France en 1998 : première et deuxième doses. BEH 1999, 19: 74–5. Antona D, Guérin N: Couverture vaccinale rougeole – rubéole – oreillons en France en 1998 : première et deuxième doses. BEH 1999, 19: 74–5.
46.
go back to reference Le Pen C, Levy E: Socio-économie de la maladie veineuse : les enseignements d'une enquête sur les consommateurs de médicaments phlébotoniques en France. Phlébologie 1993,46(n°1):47–63.PubMed Le Pen C, Levy E: Socio-économie de la maladie veineuse : les enseignements d'une enquête sur les consommateurs de médicaments phlébotoniques en France. Phlébologie 1993,46(n°1):47–63.PubMed
47.
go back to reference Mangione CM: The National Eye Institute 25-item Visual Function, Questionnaire (VFQ-25) – Scoring algorithm. 2000, 1–15. Mangione CM: The National Eye Institute 25-item Visual Function, Questionnaire (VFQ-25) – Scoring algorithm. 2000, 1–15.
48.
go back to reference Mangione CM, Berry S, Spritzer K, Kanz NK, Klein R, Owsley C, LPP : Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Archives of Ophthalmology 1998, 116: 227–33.PubMed Mangione CM, Berry S, Spritzer K, Kanz NK, Klein R, Owsley C, LPP : Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Archives of Ophthalmology 1998, 116: 227–33.PubMed
49.
go back to reference Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD: Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Archives of Ophthalmology 1998, 116: 1496–504.PubMedCrossRef Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD: Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Archives of Ophthalmology 1998, 116: 1496–504.PubMedCrossRef
50.
go back to reference Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RI, National Eye Institute Visual Function Questionnaire Field Test Investigators: Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology 2001,119(7):1050–1058.PubMedCrossRef Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RI, National Eye Institute Visual Function Questionnaire Field Test Investigators: Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology 2001,119(7):1050–1058.PubMedCrossRef
51.
go back to reference Nordmann JP, Sullivan K, Viala M, Arnoult B, Berdeaux G: Psychometric validation of the NEI-VFQ 25 French version in a population of patients treated for ocular hypertension and glaucoma. PharmacoEconomics, in press. Nordmann JP, Sullivan K, Viala M, Arnoult B, Berdeaux G: Psychometric validation of the NEI-VFQ 25 French version in a population of patients treated for ocular hypertension and glaucoma. PharmacoEconomics, in press.
53.
go back to reference International Medical Statistics, Paris 2001. International Medical Statistics, Paris 2001.
54.
go back to reference Guttman L: The qualification of a class of attributes: a theory and method of a scale construction. In: The Prediction of Personal Adjustment (Edited by: Horst P). New York: SSCR 1941, 251–264. Guttman L: The qualification of a class of attributes: a theory and method of a scale construction. In: The Prediction of Personal Adjustment (Edited by: Horst P). New York: SSCR 1941, 251–264.
55.
go back to reference Burt C: The factorial analysis of qualitative data. British Journal of Statistical Psychology 1950, 3: 166–185.CrossRef Burt C: The factorial analysis of qualitative data. British Journal of Statistical Psychology 1950, 3: 166–185.CrossRef
56.
go back to reference Hayashi C: Theory and examples of quantification (II). Proceedings of the Institute of Statistics and Mathematics 1956, 4: 19–30. Hayashi C: Theory and examples of quantification (II). Proceedings of the Institute of Statistics and Mathematics 1956, 4: 19–30.
Metadata
Title
Vision related quality of life and topical glaucoma treatment side effects
Authors
Jean-Philippe Nordmann
Nadia Auzanneau
Séverine Ricard
Gilles Berdeaux
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2003
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-1-75

Other articles of this Issue 1/2003

Health and Quality of Life Outcomes 1/2003 Go to the issue